Terapevticheskii Arkhiv最新文献

{"title":"[History of the development of insulin pump therapy technology].","authors":"P A Kazaryan, K A Golosov, I V Poluboyarinova, V V Fadeev","doi":"10.26442/00403660.2026.01.203508","DOIUrl":"10.26442/00403660.2026.01.203508","url":null,"abstract":"<p><p>The twentieth century marked a golden age for endocrinology, particularly in the methods used to treat type 1 diabetes mellitus. One of the most significant advancements during this period was the development of the insulin pump. This technology, which initially adhered to the original principles and goals of diabetes management, has undergone a remarkable evolution. The transition from large, impractical devices that were suitable only for research in clinical settings, and often associated with complications, to portable, user-friendly, and safe devices has been substantial. This evolution has facilitated the integration of insulin pumps into everyday clinical practice. A detailed examination of the journey from the first prototype of the insulin pump to the models developed by the early 1990s illustrates how researchers overcame numerous challenges. Their efforts laid the groundwork for contemporary understandings of pump insulin therapy and the realization of the aspiration for an artificial pancreas.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"98 1","pages":"81-87"},"PeriodicalIF":0.3,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146228759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Cryptogenic steatotic liver disease: a clinical and instrumental study].","authors":"A A Goncharov, V A Isakov, I V Maev","doi":"10.26442/00403660.2025.12.203453","DOIUrl":"10.26442/00403660.2025.12.203453","url":null,"abstract":"<p><strong>Background: </strong>Recent classification of steatotic liver disorders was published in 2023, where a new form - cryptogenic steatotic liver disease (CSLD) was introduced.</p><p><strong>Aim: </strong>To assess the prevalence of CSLD within the spectrum of liver disorders associated with steatosis, and to describe its clinical and instrumental characteristics.</p><p><strong>Materials and methods: </strong>A retrospective search was performed in the database of subjects underwent vibration-controlled transient liver elastography (<i>n</i>=4,673). Criteria of CSLD and other steatotic liver diseases were based on EASL guidelines. Liver stiffness and data of controlled attenuation parameter assessment were used to establish stage of liver fibrosis and degree of steatosis of the liver. Body composition was evaluated using bioimpedance analysis. Serum parameters of lipid and carbohydrate metabolism were assessed.</p><p><strong>Results: </strong>CSLD was found in 22 (0.8%) of total number of subjects with the presence of hepatic steatosis (<i>n</i>=2,643). Advanced stages of fibrosis (F2-F4) and degree of steatosis (S3) were less prevalent in CSLD group compared to MASLD: 9.1% vs 29.3%; <i>p</i>=0.02; S3 27.3% vs 67.6%; <i>p</i><0.001 accordingly. Compared to the control group (<i>n</i>=266) without steatosis and fibrosis, patients with CSLD had a greater body mass index (Median [Q1-Q3]: 24.1 [22.1-24.5] kg/m² vs 22.4 [20.7-23.7] kg/m²; <i>p</i>=0.008), primarily due to greater fat mass (19.0 [16.6-26.7] kg vs 16.4 [12.2-20.5] kg; <i>p</i>=0.03). No significant difference was found between the CSLD and the control group on the demographic characteristics, serum lipid and carbohydrate metabolism parameters.</p><p><strong>Conclusion: </strong>CSLD is a rare condition. Patients with CSLD had greater fat mass compared to the control group; however, both groups were characterized by normal values of body mass index, serum lipid and carbohydrate metaboliс parameters.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 12","pages":"987-993"},"PeriodicalIF":0.3,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Dynamics of mortality from causes directly attributable to alcohol and their contribution to all-cause mortality in the Russian Federation].","authors":"E M Osmanov, V A Reshetnikov, T M Akaev, B S Khamzaev, M A Omarov","doi":"10.26442/00403660.2025.12.203466","DOIUrl":"10.26442/00403660.2025.12.203466","url":null,"abstract":"<p><strong>Background: </strong>High level of alcohol consumption is one of the significant problems not only of public health, but also of the state as a whole.</p><p><strong>Aim: </strong>To study the dynamics and structure of mortality from causes directly related to alcohol in the Russian Federation for 2016-2023.</p><p><strong>Materials and methods: </strong>The study is retrospective, analytical, and descriptive in design. The mortality analysis was conducted based on data provided by the Federal State Statistics Service for 2016-2023.</p><p><strong>Results: </strong>It has been established that in the Russian Federation, mortality from causes directly related to alcohol decreases annually, as well as a decrease in the proportion of deaths from causes related to alcohol in the structure of all causes of mortality. In the structure of mortality from alcohol-associated causes, 5 nosologies account for more than 90% of cases, which include alcoholic cardiomyopathy, accidental alcohol poisoning, alcoholic liver disease, degeneration of the nervous system, as well as poisoning and exposure to alcohol with undetermined intent.</p><p><strong>Conclusion: </strong>The efforts of government bodies at all levels should be directed to a greater extent not at introducing prohibitive measures, which are undoubtedly effective, but at the spiritual and moral development of the individual who rejects alcohol.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 12","pages":"981-986"},"PeriodicalIF":0.3,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Idiopathic recurrent pericarditis: Yesterday, today, and tomorrow].","authors":"A А Safiullina, A A Petrukhina, Y F Osmolovskaya, I V Zhirov, S N Tereshchenko","doi":"10.26442/00403660.2025.12.203447","DOIUrl":"10.26442/00403660.2025.12.203447","url":null,"abstract":"<p><p>Idiopathic recurrent pericarditis (IRP) is an orphan inflammatory disease of the pericardium, characterised by the absence of pathognomonic symptoms and specific biomarkers. The diagnosis is complicated by the absence of characteristic clinical signs and the lack of specific markers for the recurrence of IRP, which hampers the timely initiation of pathogenetic therapy and significantly worsens the prognosis. To address the challenges of complex differential diagnosis, low physician awareness, and the lack of unified guidelines for IRP for general practitioners, internists, and cardiologists, it was necessary to establish a specialized expert center. This center aims to provide synergy among highly qualified doctors from various specialisations for precise diagnosis confirmation.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 12","pages":"965-972"},"PeriodicalIF":0.3,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Predictors of ineffective therapy in patients with rheumatoid arthritis requiring bDMARDs/JAKi switching: data from a single-center prospective study].","authors":"A O Bobkova, A M Lila, A E Karateev","doi":"10.26442/00403660.2025.12.203452","DOIUrl":"10.26442/00403660.2025.12.203452","url":null,"abstract":"<p><strong>Background: </strong>In rheumatoid arthritis (RA) the treatment target of remission or low disease activity is achieved in only 50-60% of patients, even with the use of modern targeted therapies, such as biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi). The failure of a bDMARD or JAKi necessitates switching to another treatment of these classes. However, the factors influencing the treatment effectiveness after such a switch remain unknown.</p><p><strong>Aim: </strong>To identify factors associated with poor response when switching bDMARDs/JAKi in RA patients whose previous bDMARDs/JAKi were also ineffective.</p><p><strong>Materials and methods: </strong>A total of 164 patients with RA, 46.5±14 years old, 86.6% female, RF '+' 76.8%, with Disease Activity Score - DAS28>3.2, who had failed prior bDMARD/JAKi therapy requiring a switch were enrolled. DAS28-CRP was assessed 6 months after induction of new bDMARDs/JAKi therapy. Patients with moderate/high RA activity (DAS28-CRP>3.2) were classified as non-responders (group 1), patients in remission/ low disease activity were classified as responders (group 2). Factors associated with poor response to therapy when switching bDMARDs/JAKi were identified, and then a predictive model was formed by binary logistic regression.</p><p><strong>Results: </strong>Group 1 included 80 (48.8%) patients and group 2 included 84 (51.2%) patients. Group 1 showed statistically significantly higher body mass index (BMI), later age of onset of RA, less advanced radiological stage, baseline greater TJC (tender joint count) and SJC (swollen joint count), more severe PtPGA and PhPGA, higher DAS28-CRP, CDAI and SDAI, higher PainDetect, HADS depression, FSS, CSI, FiRST, FACIT-F, higher BPI pain (for all parameters <i>p</i><0.05). A regression model for bDMARD/JAKi switching ineffectiveness with a sensitivity of 77.5% and specificity of 70.2% included BMI, RF seronegativity, CSI, PainDetect numeric score (signs of neuropathic pain), BPI (mean pain) and GC intake at baseline.</p><p><strong>Conclusion: </strong>Initial higher RA activity, pain severity, BMI, signs of central sensitisation and psychoemotional disturbance, and need for GC are associated with a poor response to therapy when switching bDMARDs/JAKi.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 12","pages":"973-980"},"PeriodicalIF":0.3,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Time to achieve target lipid metabolism parameters and its impact on long-term outcomes after acute coronary syndrome in conditions of multicomponent lipid-lowering therapy].","authors":"A A Nekrasov, E S Timoshchenko, S G Erofeeva, T A Nekrasova, F N Muradova, E S Kuzyakina","doi":"10.26442/00403660.2025.12.203499","DOIUrl":"10.26442/00403660.2025.12.203499","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the effect of the initiation time of lipid-lowering therapy (LLT) with the use of the proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor alirocumab on the incidence of adverse outcomes during 18-month follow-up after acute coronary syndrome (ACS).</p><p><strong>Materials and methods: </strong>Two groups of patients were observed. In both groups iPCSK9 alirocumab was prescribed within a year after ACS as part of multicomponent LLT: Group 1 (<i>n</i>=20) - alirocumab therapy was started 3 or more months after ACS, Group 2 (<i>n</i>=18) - alirocumab was started up to 3 months after ACS. Control visits were performed at 3, 6, 12 and 18 months after ACS to assess the character of LLT, long-term outcomes and dynamics of low-density lipoprotein cholesterol.</p><p><strong>Results: </strong>In groups 1 and 2, the proportions of those who achieved the target low-density lipoprotein cholesterol after 6 and 12 months, respectively, were 40.0 and 83.3% (<i>p</i>=0.008), 55.0 and 88.9% (<i>p</i>=0.024). A more than three-fold decrease in the need for rehospitalizations for any and cardiovascular reasons was noted among patients with an earlier start of PCSK9-targeted therapy. The need for cardiovascular hospitalizations directly correlated with the period (number of months) before alirocumab was prescribed (R=0.44; <i>p</i>=0.006).</p><p><strong>Conclusion: </strong>The use of alirocumab as a part of outpatient low-density lipoprotein cholesterol LLT provides a powerful corrective effect on the lipid profile, as well as an improvement in long-term outcomes after ACS. The positive results of this therapy are especially noticeable when it is started within 3 months after the cardiovascular event.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 12","pages":"1003-1008"},"PeriodicalIF":0.3,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A clinical case of erythromelalgia in a patient comorbid with antiphospholipid syndrome].","authors":"A A Kudrjavtseva, A V Meladze, E S Trapeznikova, A R Levshina, D A Napalkov, A A Sokolova","doi":"10.26442/00403660.2025.12.203468","DOIUrl":"10.26442/00403660.2025.12.203468","url":null,"abstract":"<p><p>The article presents a clinical case of secondary erythromelalgia in a comorbid patient with antiphospholipid syndrome, accompanied by burning pain, hyperemia and swelling of the lower extremities. A comprehensive examination involving a neurologist, dermatologist, and rheumatologist was conducted to establish the diagnosis and select the optimal therapy. Significant clinical improvement in the patient's condition is demonstrated against the background of pregabalin therapy. The importance of a multidisciplinary approach and the difficulty of diagnosis due to the lack of specific examination methods and insufficient awareness of doctors about this disease are emphasized. The described case demonstrates the need for a personalized approach to managing patients with erythromelalgia to improve their quality of life.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 12","pages":"1018-1022"},"PeriodicalIF":0.3,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Safety, tolerability, and pharmacokinetics of verenafusp alfa in healthy volunteers: results of an open-label multicohort phase I study].","authors":"E A Smolyarchuk, S S Sologova, A V Bushmanova, G Z Asadova, I D Savostina, R A Khamitov, R R Shukurov, I S Lyagoskin, O A Markova, A Y Borozinets","doi":"10.26442/00403660.2025.12.203550","DOIUrl":"10.26442/00403660.2025.12.203550","url":null,"abstract":"<p><strong>Background: </strong>Enzyme replacement drugs for treatment of mucopolysaccharidosis type II (MPS II) do not penetrate the blood-brain barrier, significantly reducing their efficacy in patients with neuropathic form. Verenafusp alfa (Clotilia^®) is a recombinant fusion protein of iduronate-2-sulfatase and a monoclonal antibody Fab fragment to human insulin receptor for distribution of the enzyme into brain.</p><p><strong>Aim: </strong>To evaluate safety, tolerability, and pharmacokinetic parameters of verenafusp alfa after single intravenous administration of escalating doses in healthy volunteers.</p><p><strong>Materials and methods: </strong>This open-label, multicohort study included 20 healthy male volunteers aged 18 to 47 years (26.1±7.8 years). Verenafusp alfa was administered intravenously for 3 hours at single doses of 0.3 mg/kg (<i>n</i>=1), 0.5 mg/kg (<i>n</i>=1), 1 mg/kg (<i>n</i>=6), 2 mg/kg (<i>n</i>=6), and 3 mg/kg (<i>n</i>=6). Safety was assessed based on the incidence of clinical and laboratory adverse events (AEs) and their relationship to the investigational medicinal product. Pharmacokinetic parameters were calculated using a noncompartmental method.</p><p><strong>Results: </strong>All 20 volunteers completed the study. AEs reported in 6 (30%) volunteers were mild in severity and related to changes in individual laboratory and instrumental test data. One AE (increased bilirubin level) was possibly related to the study drug. Pharmacokinetic analysis demonstrated a dose-dependent increase in maximum concentration (C_max) from 197.60 (0.3 mg/kg) to 10,225.80 ng/mL (3 mg/kg) and area under the concentration-time curve (AUC) from 38,678.60 to 2,714,067.42 ng×min/mL respectively. The half-life ranged from 86.69 to 213.42 minutes, and clearance lowered with the increasing dose from 7.67 to 1.11 mL/min/kg.</p><p><strong>Conclusion: </strong>Single intravenous administration of verenafusp alfa at doses ranging from 0.3 to 3 mg/kg demonstrated a favorable safety profile and good tolerability in healthy volunteers. The drug's pharmacokinetics was nonlinear, with a dose-dependent increase in C_max and AUC with the dose increment. Volume of distribution volume lowered with increase of the dose.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 12","pages":"1009-1017"},"PeriodicalIF":0.3,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Problems of interpretation of clinical results of blood transfusion in the 19th century].","authors":"M S Sergeeva, T V Litvinova, N N Krylov","doi":"10.26442/00403660.2025.12.203454","DOIUrl":"10.26442/00403660.2025.12.203454","url":null,"abstract":"<p><p>In the 19th century, blood transfusions were performed according to broad indications, which makes it difficult to unify and standardize the nomenclature of previously used terms and concepts to determine the composition of patient groups. We collected and described 833 cases of intravenous blood injection for therapeutic purposes and compared the previously stated results with a modern hypothetical model of a likely favorable match of donor-recipient pairs according to the main immunological characteristics of blood, as well as studied the criteria underlying medical conclusions on the effectiveness of the procedure.</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 12","pages":"1044-1049"},"PeriodicalIF":0.3,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Probiotics' position in clinical practice: focus on the combination of <i>Lactobacillus acidophilus</i> (LA-5) and <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> (BB-12). A review].","authors":"A V Gorelov, R S Kozlov, I V Andreeva, A A Arova, I A Bavykina, M S Grigorovich, E V Dovgan, K D Ermolenko, O V Zaytseva, S M Zakharenko, V V Zelenskaia, S K Zyryanov, N A Ilyenkova, M A Kachkovskii, T A Kogut, E G Kondyurina, V V Krasnov, E E Lokshina, V F Privorotsky, M N Repetskaya, M F Rzyankina, S N Serikova, O U Stetsiouk, D V Usenko, L V Khanipova, A M Shabalov, M A Shevyakov, L V Yakovleva","doi":"10.26442/00403660.2025.12.203481","DOIUrl":"10.26442/00403660.2025.12.203481","url":null,"abstract":"<p><p>Probiotics are currently widely used in clinical practice to prevent and treat a wide range of diseases. The purpose of our review is to highlight what we consider to be the most significant clinical studies on the use of probiotics for preventing antibiotic-associated diarrhea, clostridial diarrhea and pseudomembranous colitis. The article also presents the results of studies confirming the efficacy of probiotics in <i>Helicobacter pylori</i> eradication therapy. The review focuses on Linex^® Forte, medicinal product containing the combination of <i>Lactobacillus acidophilus </i>(LA-5) and <i>Bifidobacterium animalis</i> subsp.<i> lactis</i> (BB-12).</p>","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 12","pages":"1037-1043"},"PeriodicalIF":0.3,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}